Savolitinib plus osimertinib, already approved in China, just had its NDA submitted to the FDA after strong results in the global SAFFRON trial. What’s striking? In patients whose cancer had progressed after initial targeted therapy, this combo nearly doubled progression-free survival compared to chemo; 8.2 months vs 4.5. And in those who hadn’t yet tried third-gen EGFR drugs, it pushed that to 9.8 months. What does this mean? It could become the new go-to option for a specific subset of NSCLC patients; those with both EGFR mutation and MET amplification; a group that often runs out of options fast. The safety profile held up too, with no new red flags. If approved, this isn’t just another drug; it’s a precision medicine win that could change the sequencing of treatments in advanced lung cancer. Timing is everything; and this might be exactly what some patients need, right now.